
    
      I). Study end points Primary end point: Patient survival, including overall survival and
      progression-free survival.

      Secondary end points:

        1. Acute toxicity during treatment

        2. Tumor response rates

        3. Sites of recurrence

        4. Long-term complications and quality of life II). Design of study

      An open-label, prospective randomized trial with two treatment arms:

        -  Arm I: Patients receive CCRT with weekly cisplatin only.

        -  Arm II: Patients receive CCRT with cisplatin plus gemcitabine. III). Study population 1)
           Number of subjects: A total of 172 patients (86 per treatment arm) will be accrued for
           this study within 4 years.

      Conduct of study
    
  